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A practical difficulty often encountered is that some patients display atypical overlapping symptoms, lacking positive serobiomarkers, making a precise differential diagnosis challenging. This article presents a typical case of MS overlapping with NMOSD, and explores the diagnostic and treatment regimens available for these patients.
Case
Half and January 2016, the patient experienced another two episodes. The AZA dose was increased to 50 mg bid. In March 2016, the patient experienced vertigo, ataxia, and nuclear facial sensory disturbance on the left side. The symptoms were due to a lesion in the left middle cerebellar peduncle ( Fig.1 g-i) . The diagnosis was revised to MS.
Oral steroids and AZA were discontinued and treatment changed to standard interferon β-1b (Betaferon, Bayer) from 25 April to 20 September. The patient experienced another three episodes during this period. The use of interferon β-1b was discontinued due to poor efficacy and pronounced depression in the patient. On
October 11 th , the patient experienced dizziness, tinnitus in the left ear and weakness in both lower limbs; these symptoms exacerbated, leading to paralysis and sensory loss in the lower limbs and bed-ridden. Multiple lesions were identified in the spinal cord ( Fig.1 j-k) . The patient was hospitalized for a total of 127 days in the one year and three months since disease onset. Treatment was then changed to 1000 mg (subdivided into 2 infusions given within half a month) rituximab (Roche) IV every 6 months in 
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Hospital of Sun Yat-sen University. Written informed consent was obtained from the patient to publish her case report.
Discussion
The case reported here shared clinical and imaging features of NMOSD and MS.
The diagnosis of the case was difficult in part due to the fact that AQP4-IgG, It may be speculated that humoral immunity, rather than T cell-mediated immunity, may play a more important role in their pathogenesis [3, 4] .
To date, there are no clinical trials targeting patients with transitional features of both MS and NMOSD; therefore, there are no commonly accepted treatment guidelines or consensus for these patients. Waiting to reach a final diagnosis may be a reasonable choice for some, but frequent clinical relapses occur often and demand early and effective disease-modifying therapy. As humoral immunity is a shared mechanism for NMOSD and MS, treatments targeting humoral immunity may be a safe and appropriate choice [5] . Rituximab and other new B cell depleting agents such as ocrelizumab may have strong disease-modifying effects and are effective in both MS and NMOSD patients [4, 6] , suggesting that these drugs may be preferred for the challenging demyelinating case of MS overlapping NMOSD, especially in Asian populations.
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